Aqemia Secures Additional €30 Million in Series A

Aqemia Secures Additional €30 Million in Series A

Aqemia, a Paris, France-based tech-enabled drug discovery company, has secured an additional €30 million in funding, bringing its Series A round to a total of €60 million.

Wendel Growth led the investment, and existing partners Bpifrance Large Venture, Eurazeo, and Elaia also participated.

Wendel Growth is an investment arm of Wendel, a family-held investment company operating at the crossroads of industry and finance. Based in Paris, France, the firm invests in innovative, high-growth companies. Wendel's ambition is to invest up to €50 million per unit in scale-ups in Europe and North America. At the same time, Wendel Growth is continuing to invest in funds and funds of funds.

The company plans to use the funding to accelerate the growth of its pipeline of drug discovery projects, which includes assets in oncology and immuno-oncology.

Aqemia is a pharmatech company using quantum physics and artificial intelligence to transform the drug discovery process. The company leverages its proprietary GenAI and deep physics drug discovery platform to enhance its drug discovery efforts. The company recently signed a $140 million drug discovery deal with Sanofi. Its mission is to design fast innovative drug candidates for dozens of critical diseases.

Funding Details

Company: Aqemia

Raised: €30.0M

Round: Series A

Funding Month: January 2024

Lead Investors: Wendel Growth

Additional Investors: Bpifrance Large Venture, Eurazeo, and Elaia

Company Website: https://www.aqemia.com/

Software Category: Drug Discovery